PRCT logo

PROCEPT BioRobotics Corporation (PRCT)

$23.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on PRCT

Market cap

$1.37B

EPS

-2.03

P/E ratio

--

Price to sales

3.12

Dividend yield

--

Beta

0.871625

Price on PRCT

Previous close

$23.54

Today's open

$23.36

Day's range

$23.03 - $24.11

52 week range

$16.67 - $38.11

Profile about PRCT

CEO

Larry Wood

Employees

888

Headquarters

San Jose, CA

Exchange

NASDAQ Global Market

Shares outstanding

57536121

Issue type

Common Stock

PRCT industries and sectors

Healthcare

Medical Equipment & Supplies

News on PRCT

PROCEPT BioRobotics Q3 Earnings Call Highlights

PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.

news source

MarketBeat • Nov 5, 2026

news preview

PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript

PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 4, 2026

news preview

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.38 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

PROCEPT BIOROBO (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth

PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.

news source

Seeking Alpha • Oct 23, 2026

news preview

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

news source

GlobeNewsWire • Oct 12, 2026

news preview

PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation

SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit has been filed concerning certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT). Investors who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or +1 (858) 779-1554.

news source

PRNewsWire • Oct 1, 2026

news preview

LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation

A lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation

news source

GlobeNewsWire • Sep 30, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PROCEPT BioRobotics Corporation of Class Action Lawsuit and Upcoming Deadlines – PRCT

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

news source

GlobeNewsWire • Sep 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in PROCEPT BioRobotics Corporation

Open an M1 investment account to buy and sell PROCEPT BioRobotics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in PRCT on M1